Why does no GLP-1 dose fit someone between the trial cohorts?
Tirzepatide and semaglutide doses jump in big steps. Anyone whose tolerance sits between 5 mg and 7.5 mg cycles through nausea, plateaus, and unauthorized self-titration. Telehealth clinicians won't deviate from the label.
Category: HealthTech · Trend: AI · Opportunity score: 8.0 / 10
What is the “Why does no GLP-1 dose fit someone between the trial cohorts?” problem in 2026?
Tirzepatide and semaglutide doses jump in big steps. Anyone whose tolerance sits between 5 mg and 7.5 mg cycles through nausea, plateaus, and unauthorized self-titration. Telehealth clinicians won't deviate from the label.
Who has this problem?
GLP-1 patients on Zepbound, Wegovy, Mounjaro, Ozempic who can't tolerate the next labelled dose.
Recorded source context
Dataset source note: 5 mg works for two weeks then plateaus. 7.5 mg puts me in bed for three days. My telehealth doc says that's not a thing. The subreddit has 4,000 of us doing micro-doses with kitchen scales.
This note may summarize the referenced material rather than quote it verbatim. Source label: r/Mounjaro, r/Zepbound, r/Ozempic dose-titration megathreads with 10K+ comments through 2025 and 2026..
Existing players in this space
- Telehealth clinics (Ro, Hims, Sequence): Stick to label, won't customise between doses
- Compounded pharmacies: Mostly delisted post-FDA shortage end, legally squeezed
- Reddit DIY titration spreadsheets: Best resource patients have today, unsupervised
What existing players are missing
An evidence-curated micro-titration coach: log side-effect patterns, weight, food intake, suggest the dose the patient's GP can actually prescribe under shared-decision-making, with the citations attached. Connects to a real prescriber for the off-label step, not a vending machine.
How Real Problem AI scores this opportunity
Aggregate score: 8.0 / 10. Four-axis rubric:
- Problem severity: 8 / 10
- AI feasibility today: 7 / 10
- Market signal: 9 / 10
- Competition gap: 8 / 10
How to build a solution: stack hints
- Symptom and dose journal with side-effect taxonomy
- Curated trial and registry data, citation-first responses
- Shared-decision-making PDF the patient walks into their GP's office with
- Prescriber network for off-label dosing where allowed
Why this problem is archived
Swapped out in AI-tool-builder content refresh (2026-08-26): generic vertical problem replaced by a more current, builder-relevant one.
Related HealthTech problems on Real Problem AI
- Why is finding an in-network therapist with availability actually impossible? (9.3/10)
- Why can't a GLP-1 patient find which compounding pharmacy actually has tirzepatide in stock today? (9.3/10)
- Why does my $4k hospital bill have charges I can't decode and probably overpaid? (8.9/10)
- Why does my doctor spend the visit typing instead of looking at me? (8.8/10)
- Why does every ABA clinic still hand-write SOAP notes that fail Medicaid audit six months later? (8.8/10)